Dendritic cell generated from CD34+ hematopoietic progenitors can be transfected with adenovirus containing gene of HBsAg and induce antigen-specific cytotoxic T cell responses

Cellular Immunology

Volumn 240, Issue 1, 2006, Pages 14-21

  Yang, Jing Yue ^a   Cao, Da Yong ^a   Liu, Wen Chao ^a   Zhang, Hong Mei ^a   Teng, Zeng Hui ^b   Ren, Jun ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Cytotoxic T lymphocytes; Dendritic cells; Immunotherapy; Liver neoplasm

Indexed keywords

ADENOVIRUS VECTOR; CD34 ANTIGEN; DENDRITIC CELL VACCINE; HEPATITIS B SURFACE ANTIGEN; HLA ANTIGEN CLASS 1;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEASIBILITY STUDY; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL LINE;

ADENOVIRIDAE; ANTIGENS, CD34; APOPTOSIS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HEPATITIS B SURFACE ANTIGENS; HUMANS; INTERFERON TYPE II; LYMPHOCYTE CULTURE TEST, MIXED; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 33747842848     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2006.06.005     Document Type: Article

References (40)

1. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 25 (2005) 143-154
2. Lai EC., and Lau WY. The continuing challenge of hepatic cancer in Asia. Surgeon 3 (2005) 210-215
3. Merican I., Guan R., Amarapuka D., et al. Chronic hepatitis B virus infection in Asian countries. J. Gastroenterol. Hepatol. 15 (2000) 1356-1361
4. Blum H.E. Hepatocellular carcinoma: therapy and prevention. World J. Gastroenterol. 11 (2005) 7391-7400
5. Banchereau J., Schuler-Thurner B., Palucka A.K., et al. Dendritic cells as vectors for therapy. Cell 106 (2001) 271-274
6. Guermonprez P., Valladeau J., Zitvogel L., et al. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20 (2002) 621-667
7. Onaitis M., Kalady MF., Pruitt S., et al. Dendritic cell gene therapy. Surg. Oncol. Clin. N Am. 11 (2001) 645-660
8. Pawlowska AB., Hashino S., McKenna H., et al. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. Blood 97 (2001) 1474-1482
9. Zhang L.W., Zhan H.M., Liu W.C., et al. Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA. Cell. Immunol. 238 (2005) 61-66
10. Tong H.S., Zhang Y., Yuan K., et al. HBsAg loading on dendritic cells in patients with chronic hepatitis B: expressions of phenotypic molecules. Hepatobiliary Pancreat Dis. Int. 1 (2006) 56-59
11. Kaplan J.M., Yu Q., Piraino S.T., et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163 (1999) 699-707
12. Arthur J.F., Butterfield L.H., Roth M.D., et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4 (1997) 17-25
13. Molinier F.V., Boulaire L.C., Le F.A., et al. Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients. Hum. Gene Ther. 13 (2000) 1911-1920
14. Eloit M., Gilardi-Hebenstreit P., Toma B., et al. Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine. J. Gen. Virol. 71 (1990) 2425-2431
15. Nishimura N., Nishioka Y., Shinohara T., et al. Novel centrifugal method for simple and highly efficient adenovirus-mediated green fluorescence protein gene transduction into human monocyte-derived dendritic cells. J. Immunol. Methods 253 (2001) 113-124
16. Gruijl D., Tanja D., Luykx D.B., et al. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J. Immunol. 9 (2002) 5322-5331
17. Eloit M., Gilardi-Hebenstreit P., Toma B., et al. Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine. J. Gen. Virol. 71 (1990) 2425-2431
18. Schoeters E., Verheyen G.R., Van Den Heuvel R., et al. Expression analysis of immune-related genes in CD34(+) progenitor-derived dendritic cells after exposure to the chemical contact allergen DNCB. Toxicol In Vitro. 19 (2005) 909-913
19. Ueno H., Tcherepanova I., Reygrobellet O., et al. Dendritic cell subsets generated from CD34+ hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses. J. Immunol. Methods 285 (2004) 171-180
20. Nakamura Y., Suda T., Nagata T., et al. Induction of protective immunity to listeria monocytogenes with dendritic cells retrovirally transduced with a cytotoxic T lymphocyte epitope minigene. Infect. Immun. 71 (2003) 1748-1754
21. Lapointe R., Royal R.E., Reeves M.E., et al. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J. Immunol. 167 (2001) 4758-4764
22. Zhang J.K., Li J., Chen H.B., et al. Antitumor activities of human dendritic cells derived from peripheral and cord blood. World J. Gastroenterol. 8 (2002) 87-90
23. Caux C., Massacrier C., Vanbervliet B., et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 90 (1997) 1458-1470
24. Banchereau J., Palucka A.K., Dhodapkar M., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61 (2001) 6451-6458
25. Bubenik J. Genetically engineered dendritic cell-based cancer vaccines. Int. J. Oncol. 18 (2001) 475-478
26. Brossart P., Goldrath A.W., Butz E.A., et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158 (1997) 3270-3276
27. Song W., Kong H.L., Carpenter H., et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186 (1997) 1247-1256
28. Butterfield L.H., Jilani S.M., Chakraborty N.G., et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J. Immunol. 161 (1998) 5607-5613
29. Rea D., Laface D., Hutchins B., et al. Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th1-type responses while selectively activating IL-10-producing CD4+ T cells. Hum. Immunol. 65 (2004) 1344-1355
30. Gahn B., Siller-Lopez F., Pirooz A.D., et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int. J. Cancer. 93 (2001) 706-713
31. Specht J.M., Wang G., Do M.T., et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186 (1997) 1213-1221
32. Bronte V., Carroll M.W., Goletz T.J., et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci USA 94 (1997) 3183-3188
33. Chiriva-Internati M., Liu Y., Salati E., et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur. J. Immunol. 32 (2002) 30-38
34. Motta I., Andre F., Lim A., et al. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J. Immunol. 167 (2001) 1795-1802
35. Zhong L., Granelli-Piperno A., Choi Y., et al. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur. J. Immunol. 29 (1999) 964-972
36. Engelmayer J., Larsson M., Subklewe M., et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 163 (1999) 6762-6768
37. Ignatius R., Marovich M., Mehlhop E., et al. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J. Virol. 74 (2000) 11329-11338
38. Engelmayer J., Larsson M., Lee A., et al. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J. Virol. 75 (2001) 2142-2153
39. Ding C.L., Yao K., Zhang T.T., et al. Generation of cytotoxic T cell against HBcAg using retrovirally transduced dendritic cells. World J. Gastroenterol. 9 (2003) 1512-1515
40. Sette A.D., Oseroff C., Sidney J., et al. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus- transgenic mice. J. Immunol. 166 (2001) 1389-1397